The clinical evidence for circ‐SLC9A6 and SLC9A6‐126aa is limited, and a large clinical trial will provide valuable human somatic data for the diagnosis and therapeutic role of circ‐SLC9A6 and SLC9A6‐126aa in NAFLD. Here, SLC9A6 is linked to metabolic dysfunction-associated steatotic liver disease.